Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for BRIACELL THERAP (BCTX : NSDQ)

• Company Description    BriaCell Therapeutics Corp. is an immuno-oncology focused biotechnology company. It developed a patented whole-cell vaccine, cancer immunotherapy technology called the `BriaVax` vaccine for cancer. The company's technology consists of Bria-IMT(TM), Bria-OTS(TM) and BriaDx(TM) which are in clinical stage. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada. Number of Employees: 22

• Price / Volume Information    Yesterday's Closing Price: $11.31 Daily Weekly Monthly 20 Day Moving Average: 84,415 shares Shares Outstanding: 0.68 (millions) Market Capitalization: $7.66 (millions) Beta: 1.21 52 Week High: $190.50 52 Week Low: $6.00 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -8.79% -11.18% 12 Week 52.84% 46.50% Year To Date -86.65% -88.33%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 235 15th Street Suite 300 - WEST VANCOUVER,A1 V7T 2X1 CAN ph: 604-921-1810 fax: 604-921-1898 investors@briacell.com https://briacell.com

• General Corporate Information    Officers William V. Williams - President; Chief Executive Officer; and Director Jamieson Bondarenko - Chairman of the Board of Directors Gadi Levin - Chief Financial Officer and Corporate Secretary Vaughn C. Embro-Pantalony - Director Martin E. Schmieg - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 107930307 SIC: 2834 Fiscal Year Fiscal Year End: July Last Reported Quarter: 04/01/25 Next Expected EPS Date: 12/15/25 Share - Related Items Shares Outstanding: 0.68 Most Recent Split Date: 8.00 (0.10:1) Beta: 1.21 Market Capitalization: $7.66 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 12/15/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.44 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -199.44% vs. Previous Quarter: 29.61% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 10/31/25 - - 07/31/25 - -291.42 04/30/25 - -479.97 ROA 10/31/25 - - 07/31/25 - -180.62 04/30/25 - -182.26 Current Ratio 10/31/25 - - 07/31/25 - 5.01 04/30/25 - 3.41 Quick Ratio 10/31/25 - - 07/31/25 - 5.01 04/30/25 - 3.41 Operating Margin 10/31/25 - - 07/31/25 - - 04/30/25 - - Net Margin 10/31/25 - - 07/31/25 - - 04/30/25 - - Pre-Tax Margin 10/31/25 - - 07/31/25 - - 04/30/25 - - Book Value 10/31/25 - - 07/31/25 - 25.58 04/30/25 - 18.21 Inventory Turnover 10/31/25 - - 07/31/25 - - 04/30/25 - - Debt-to-Equity 10/31/25 - - 07/31/25 - 0.00 04/30/25 - 0.00 Debt-to-Capital 10/31/25 - - 07/31/25 - 0.00 04/30/25 - 0.00

Powered by Zacks Investment Research ©